By combining these assays with an aggregate α-synuclein ELISA, we highlight the ability of these assays to leverage novel biological insights into α-synuclein biology from established synucleinopathy mouse models by enabling quantification of both pS129 α-synuclein and aggregate pathology in these models. This evidence concerns the gene SNCA and synucleinopathy.